| SCHEDULE OF PRINCIPAL ACTIVITIES OF SUBSIDIARIES |
The
principal activities of the subsidiaries of the Company (the “Company” or collectively known as the “Group”)
are as follows:
SCHEDULE OF PRINCIPAL ACTIVITIES OF SUBSIDIARIES
| Name of entity | |
Principal activities | |
Country of
business /
incorporation | |
Group’s effective equity
interest held | |
| | |
| |
| |
2024 | | |
2025 | |
| | |
| |
| |
% | | |
% | |
| Advance Cancer Centre Pte Ltd | |
Investment, research and development of medical technologies | |
Singapore | |
| 100 | | |
| 100 | |
| | |
| |
| |
| | | |
| | |
| CytoMed Therapeutics (Malaysia) Sdn Bhd | |
Research, development and manufacturing of stem cells and innate immune cell-based immune-therapeutics, research and development of induced pluripotent stem cell-based immune-therapeutics | |
Malaysia | |
| 100 | | |
| 100 | |
| | |
| |
| |
| | | |
| | |
| LongevityBank Pte Ltd | |
Stem cell and immune cell banking | |
Singapore | |
| 90 | | |
| 77+ | |
| | |
| |
| |
| | | |
| | |
| Held by LongevityBank Pte Ltd | |
| |
| |
| | | |
| | |
| | |
| |
| |
| | | |
| | |
| IPSC Depository Sdn Bhd | |
Processing and banking of cells including cord blood stem cells and development on cell-based therapy | |
Malaysia | |
| 90 | | |
| 77+ | |
| | |
| |
| |
| | | |
| | |
| Puricell Lab Pte Ltd | |
Research and development of induced pluripotent stem cell-based biologics and medical technologies | |
Singapore | |
| 95 | | |
| 73+ | |
+
Rounded to the nearest whole %
|
| SCHEDULE OF FINANCIAL INFORMATION OF NON-CONTROLLING INTERESTS |
The
following table illustrates the summarized financial information of the Group’s material NCI (and not the Group’s share of
those amounts), adjusted for difference in accounting policies between the Group and the subsidiaries, if any.
SCHEDULE OF FINANCIAL INFORMATION OF NON-CONTROLLING INTERESTS
| | |
2023 | | |
2024 | | |
2025 | |
| | |
S$ | | |
S$ | | |
S$ | |
| | |
| | |
| | |
| |
| Revenue | |
| - | | |
| 69,501 | | |
| 324,387 | |
| Loss before tax | |
| - | | |
| (96,735 | ) | |
| (158,832 | ) |
| Income tax expenses | |
| - | | |
| - | | |
| - | |
| Loss after tax | |
| - | | |
| (96,735 | ) | |
| (158,832 | ) |
| Loss allocated to NCI | |
| - | | |
| (5,163 | ) | |
| (15,879 | ) |
| Other comprehensive gain allocated to NCI | |
| - | | |
| - | | |
| - | |
| Total comprehensive loss allocated to NCI | |
| - | | |
| (5,163 | ) | |
| (15,879 | ) |
| | |
| | | |
| | | |
| | |
| Cash flows generated from operating activities | |
| - | | |
| 32,697 | | |
| 306,016 | |
| Cash flows used in investing activities | |
| - | | |
| (808,924 | ) | |
| (455,463 | ) |
| Cash flows generated from financing activities | |
| - | | |
| 849,938 | | |
| 700,000 | |
| Net cash inflows | |
| - | | |
| 73,711 | | |
| 550,553 | |
| | |
2023 | | |
2024 | | |
2025 | |
| | |
S$ | | |
S$ | | |
S$ | |
| | |
| | |
| | |
| |
| Current assets | |
| - | | |
| 141,490 | | |
| 827,839 | |
| Non-current assets | |
| - | | |
| 811,158 | | |
| 1,226,368 | |
| Current liabilities | |
| - | | |
| (174,894 | ) | |
| (656,069 | ) |
| Non-current liabilities | |
| - | | |
| (31,290 | ) | |
| (52,582 | ) |
| Net (liabilities)/assets | |
| - | | |
| 746,464 | | |
| 1,345,556 | |
| | |
| | | |
| | | |
| | |
| Accumulated NCI | |
| - | | |
| 77,749 | | |
| 309,221 | |
| Less: fair value adjustments | |
| - | | |
| - | | |
| - | |
| Adjusted accumulated NCI | |
| - | | |
| 77,749 | | |
| 309,221 | |
|